Cost-effectiveness analysis of three kinds of schemes in the treatment of acute exacerbation of chronic bronchitis
10.3760/cma.j.issn.1008-6706.2014.06.035
- VernacularTitle:三种方案治疗慢性支气管炎急性发作的成本-效果分析
- Author:
Hongliang ZHENG
;
Songyang ZHONG
;
Zhanchi XU
- Publication Type:Journal Article
- Keywords:
Bronchitis,chronic;
Cost-effectiveness analysis
- From:
Chinese Journal of Primary Medicine and Pharmacy
2014;21(6):878-879
- CountryChina
- Language:Chinese
-
Abstract:
Objective From the point of view of pharmaceutical economics,to analyze and compare the clinical efficacy,safety,compliance and economic effect of three kinds of scheme:1.moxifloxacin,2.moxifioxacin combined with ambroxol,3.azithromycin combined with levofloxacin in the treatment of acute exacerbation of chronic bronchitis (AECB).Methods Retrieval Chinese joumal full-text database,Wanfang medical database and Chinese science and technology periodical full-text database,included three options for the treatment of AECB randomized controlled trial (RCT) literature,through the analysis of the data to make drug economics evaluation.Results The total effective rates of three programs were 94.92％,95.08％,94.90％,the difference was not statistically significant (P ＞ 0.05).The cost-effectiveness ratios were 213.34,536.40,61.22.Conclusion The efficacy of three treatment options is similar,azithromycin combined with levofloxacin has economic advantages.
